Immunocore Reports Second Quarter Financial Results And Provides A Business Update
RefinitivMenos de 1 minuto de lectura
Immunocore Holdings PLC 
IMCR:
IMMUNOCORE REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE
IMMUNOCORE : PHASE 3 TEBE-AM TRIAL REMAINS ON SCHEDULE TO COMPLETE ENROLLMENT IN THE FIRST HALF OF 2026
IMMUNOCORE : KIMMTRAK®(TEBENTAFUSP-TEBN) NET REVENUES OF $98.0 MILLION IN Q2 2025
Inicie sesión o cree una cuenta gratuita y permanente para leer esta noticia